Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | BCDIN3D | Q7Z5W3 | 6/20 | 0.34 |
| ▸ | GART | P22102 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128414 | 0.92 | SYK (0.38) | SYKBCDIN3DP2RX7MEN1KMT2A | |
| SCHEMBL10128419 | 0.90 | SYK (0.39) | SYKBCDIN3DP2RX7PTK6MEN1 | |
| SCHEMBL10158084 | 0.87 | SYK (0.36) | SYKBCDIN3DP2RX7MEN1KMT2A | |
| SCHEMBL10128468 | 0.86 | PTK6 (0.40) | SYKBCDIN3DPTK6 | |
| SCHEMBL16305357 | 0.85 | SYK (0.38) | SYKBCDIN3DP2RX7MAP4K1 | |
| SCHEMBL10128490 | 0.84 | SYK (0.38) | SYKBCDIN3DJAK2 | |
| SCHEMBL10128675 | 0.83 | SYK (0.38) | SYKBCDIN3DJAK2MEN1KMT2A | |
| SCHEMBL10156808 | 0.82 | SYK (0.42) | SYKBCDIN3DMEN1KMT2A | |
| SCHEMBL16305358 | 0.81 | SYK (0.38) | SYKMAP4K1MEN1KMT2A | |
| SCHEMBL10128304 | 0.81 | SYK (0.40) | SYKBCDIN3DMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | SYK 2200/4885P2RX3 1856/4885BCDIN3D 274/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | SYK 2200/4885P2RX3 1856/4885BCDIN3D 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.